ABSTRACT Purpose Kidney involvement is frequent among patients with coronavirus disease 2019 (Covid-19). However, kidney involvement is varied and mild kidney injury can easily go unnoticed. We aimed to investigate the urinalysis data of Covid-19 patients on admission and to explore the value of urinalysis in the prediction of AKI and in-hospital mortality in patients with Covid-19. Methods The demographic, clinical and laboratory data of patients with confirmed Covid-19 were collected from the electronic health records of the hospital. The outcomes were development of AKI and in-hospital mortality. Results 244 patients were included in the analysis. Mean age was 59.6 ± 13.7 and 65.2% of patients were male. Median SCr on admission was 0.86 (0.72-1.05) mg/dL. Glucosuria, proteinuria and hematuria were found in 36.1%, 22.9% and 22.1% of patients, respectively. AKI was detected in 63 patients (25.8%) on any time of hospitalization. According to multivariate binary logistic regression analayses; AKI development was associated with higher WBC and decreased eGFR as well as with proteinuria on admission. During median 8 (IQR, 5-12) days of follow-up, 33 patients (13.5%) died. Older age, higher CRP levels and proteinuria on admission were also independent predictors of in-hospital mortaliy. Conclusion Proteinuria on admission is associated with development of AKI and in-hospital mortality in patients with Covid-19. Urinalysis can be useful for the evaluation of COVID-19 progression and early diagnosis of kidney damage before SCr rise.

Introduction: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus (HCV) in the world. Aims: The aim of this study was to compare direct acting antivirals (DAAs) treatment of HCV for PWID and non-PWID in real life setting. Materials and methods: We performed a prospective, non-randomized, observational multi-center cohort study in 37 centers. All patients treated with DAAs therapy between April 1, 2017 to February 28, 2019 were included. In total, 2,713 patients were included in the study among which 250 were PWID and 2,463 were non-PWID. Besides patient characteristics, treatment response, follow-up and side effects of treatment were also analyzed. Results: Genotype 1a and 3 were more prevalent in PWID infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naïve patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). Conclusion: DAAs were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization’s objective of eliminating viral hepatitis.